Current Status and Trends in Inflammatory Bowel Disease Surgery in Korea: Analysis of Data in a Nationwide Registry

Abstract Background Dietary modification shows promise as therapy in inflammatory bowel disease (IBD); however, it is unknown whether adolescents are interested in a dietary approach. Methods Cross-sectional survey of adolescents with IBD ages 14–21 on disease knowledge, dietary habits, and perceptions of diet therapy. Results A total of 132 subjects (48.5% female), mean age of 17.8 years and median disease length of 5 years (range 0, 16), completed the survey. Diet was perceived as a symptom trigger by 59.8% of subjects, and 45.4% had tried using diet as a treatment for symptom resolution, often without physician supervision and with limited success. Overall, subjects reported following a diet significantly more often than documented in the electronic medical record (EMR) by the physician (25.0% vs. 15.0%, p=0.033), with 72% agreement between subject response and EMR documentation on current status of diet modification (AC1=0.59, CI=0.45, 0.73). Subjects experiencing active disease symptoms as determined by Manitoba IBD Index were more likely to be currently modifying their diet compared to subjects without active disease symptoms (OR = 4.11, CI=1.58, 10.73, p=0.003). The subjects reporting unsuccessful dietary modification compliancy (25.7%, n=34) most commonly cited perceived lack of improvement in their IBD symptoms as the primary reason for stopping the diet (48.4%, n=15). Conclusions Adolescents with IBD perceive a relationship between diet and disease symptoms and are interested in dietary modification as a symptom management option. Our study suggests that a large proportion of adolescent IBD patients may already be attempting dietary modification, and therefore would be receptive to a modified dietary plan under the guidance of their gastroenterologist and dietitian. Much is still unknown about how dietary modification will fit in with current treatment regimens, but patient interest informs us that it is necessary to continue development and research of this promising therapeutic option.

Download Full-text

P140 CURRENT STATUS OF HOME INFUSIONS FOR INFLAMMATORY BOWEL DISEASE IN THE UNITED STATES

Gastroenterology ◽

10.1053/j.gastro.2017.11.187 ◽

2018 ◽

Vol 154 (1) ◽

pp. S72-S73 ◽

Cited By ~ 1

Author(s):

Bharati Kochar ◽

Yue Jiang ◽

Christopher F. Martin ◽

Edward L. Barnes ◽

Millie D. Long

Keyword(s):

United States ◽

Inflammatory Bowel Disease ◽

Bowel Disease ◽

The United States ◽

Current Status ◽

Inflammatory Bowel

Download Full-text

The Microbiome in Inflammatory Bowel Disease: Current Status and the Future Ahead

Gastroenterology ◽

10.1053/j.gastro.2014.02.009 ◽

2014 ◽

Vol 146 (6) ◽

pp. 1489-1499 ◽

Cited By ~ 786

Author(s):

Aleksandar D. Kostic ◽

Ramnik J. Xavier ◽

Dirk Gevers

Keyword(s):

Inflammatory Bowel Disease ◽

Bowel Disease ◽

Current Status ◽

The Future ◽

Inflammatory Bowel

Download Full-text

Application of Proteomics to Inflammatory Bowel Disease Research: Current Status and Future Perspectives

Gastroenterology Research and Practice ◽

10.1155/2019/1426954 ◽

2019 ◽

Vol 2019 ◽

pp. 1-24 ◽

Cited By ~ 3

Author(s):

Arash Assadsangabi ◽

Caroline A. Evans ◽

Bernard M. Corfe ◽

Alan Lobo

Keyword(s):

Inflammatory Bowel Disease ◽

Cancer Progression ◽

Bowel Disease ◽

Biomarker Discovery ◽

Association Studies ◽

Disease Process ◽

Current Status ◽

Genome Wide Association Studies ◽

Susceptibility Loci ◽

Inflammatory Bowel

Inflammatory bowel disease (IBD) is a chronic relapsing/remitting inflammatory illness of the gastrointestinal tract of unknown aetiology. Despite recent advances in decoding the pathophysiology of IBD, many questions regarding disease pathogenesis remain. Genome-wide association studies (GWAS) and knockout mouse models have significantly advanced our understanding of genetic susceptibility loci and inflammatory pathways involved in IBD pathogenesis. Despite their important contribution to a better delineation of the disease process in IBD, these genetic findings have had little clinical impact to date. This is because the presence of a given gene mutation does not automatically correspond to changes in its expression or final metabolic or structural effect(s). Furthermore, the existence of these gene susceptibility loci in the normal population suggests other driving prerequisites for the disease manifestation. Proteins can be considered the main functional units as almost all intracellular physiological functions as well as intercellular interactions are dependent on them. Proteomics provides methods for the large-scale study of the proteins encoded by the genome of an organism or a cell, to directly investigate the proteins and pathways involved. Understanding the proteome composition and alterations yields insights into IBD pathogenesis as well as identifying potential biomarkers of disease activity, mucosal healing, and cancer progression. This review describes the state of the art in the field with respect to the study of IBD and the potential for translation from biomarker discovery to clinical application.

Download Full-text

Genetics of Inflammatory Bowel Disease: Current Status and Future Directions

Canadian Journal of Gastroenterology ◽

10.1155/2006/326025 ◽

2006 ◽

Vol 20 (10) ◽

pp. 633-639 ◽

Cited By ~ 8

Author(s):

Thomas D Walters ◽

Mark S Silverberg

Keyword(s):

Inflammatory Bowel Disease ◽

Bowel Disease ◽

Current Status ◽

Future Directions ◽

Inflammatory Bowel

Download Full-text

Current status of ileorectal anastomosis for inflammatory bowel disease

Diseases of the Colon & Rectum ◽

10.1007/bf02563692 ◽

1989 ◽

Vol 32 (5) ◽

pp. 400-403 ◽

Cited By ~ 18

Author(s):

I. T. Khubchandani ◽

M. R. Sandfort ◽

L. Rosen ◽

J. A. Sheets ◽

J. J. Stasik ◽

...

Keyword(s):

Inflammatory Bowel Disease ◽

Bowel Disease ◽

Ileorectal Anastomosis ◽

Current Status ◽

Inflammatory Bowel

Download Full-text

Current status of cytomegalovirus colitis among patients with inflammatory bowel disease in China: A questionnaire-based multi-center study

Inflammatory Bowel Diseases ◽

10.1093/ibd/izab358 ◽

2022 ◽

Author(s):

Hong Yang ◽

Jiaming Qian

Keyword(s):

Inflammatory Bowel Disease ◽

Bowel Disease ◽

Capital City ◽

Current Status ◽

Chi Square ◽

Provincial Capital ◽

Inflammatory Bowel ◽

Multi Center Study ◽

Cmv Colitis ◽

Center Study

Abstract Background Cytomegalovirus (CMV) causes infection in patients with inflammatory bowel disease (IBD). This study investigated the prevalence of CMV colitis, the current status of laboratory testing equipment, and physicians’ opinions regarding CMV and IBD in China. Methods This retrospective multi-center study was conducted by Chinese members of the Asian Organization for Crohn’s and Colitis and included 36 hospitals/institutes divided according to municipality, provincial capital city, and prefectural-level city. A survey questionnaire was administered, and chi-square and Fisher’s exact tests were performed. Results A total of 4 823 inpatients with ulcerative colitis (UC) and 4.622 inpatients with Crohn’s disease (CD) were included. The percentages of patients with moderate UC in the provincial capital city and municipality were significantly higher than that in the prefectural-level city (38.3% vs. 29.1% and 40.1% vs. 29.1%, respectively). The percentage of patients with mild CD was significantly lower in the provincial capital city than in the prefectural-level city and municipality (30.4% vs. 40.3%; 30.4% vs. 39.3%, respectively). There were 3.1% patients with UC and 0.8% patients with CD who had CMV colitis. The prevalence of CMV colitis was lower in patients with CD than in patients with UC (0.8% vs. 3.1%). Of the 150 patients with UC and concurrent CMV colitis, 17.3% patients underwent surgery, 2.0% died, and 23.3% experienced complications. Punched-out ulcerations were the major characteristic features for detecting CMV colitis. Approximately 77.8% of hospitals possessed testing facilities capable of conducting CMV immunohistochemistry. Conclusions CMV colitis is an important issue during the disease progression of IBD. However, improvement in knowledge and facilities is required to enhance the prognosis of patients.

Download Full-text

Immunosppressive Agents in Inflammatory Bowel Disease: Current Status and Future Prospects

Canadian Journal of Gastroenterology ◽

10.1155/1994/580410 ◽

1994 ◽

Vol 8 (6) ◽

pp. 383-387

Author(s):

Fergus Shanahan ◽

Gerald C O'’Sullivan ◽

J Kevin Collins

Keyword(s):

Ulcerative Colitis ◽

Inflammatory Bowel Disease ◽

Crohn’S Disease ◽

Crohn's Disease ◽

Bowel Disease ◽

Tissue Injury ◽

Current Status ◽

Mucosal Inflammation ◽

Clinical Role ◽

Inflammatory Bowel

Inflammatory bowel disease involves an interaction between genetic susceptibility factors and environmental triggers, and the intestinal injury is mediated by the host immunoinflammatory response. Identification of the mechanisms and mediators that contribute to the tissue injury has provided a sound rationale for the therapeutic use of immunosuppressive and immunomodulatory agents. The efficacy of traditional immunosuppressive drugs, such as the purine analogues in both Crohn’s disease and ulcerative colitis, is well established. The major limitation of the use of these drugs is the delayed clinical response associated with their use. This has prompted an evaluation of other immunosuppressivcs, such as cyclosporine and related drugs, that have a more rapid onset of action. Convincing data indicate a distinct role for cyclosporine in certain patients with acute severe ulcerative colitis. However, despite early promising results with cyclosporine in Crohn’s disease, recent results have been less encouraging. There is also uncertainty about the exact clinical role of cyclosporine because of concerns regarding long term toxicity. At present, many investigators regard cyclosporine as an interim measure for acutely ill patients. The challenge that remains is the development of novel immunomodulatory strategies that are specific for the mucosal immune system and that are based on recent advances in our understanding of the pathogenesis of mucosal inflammation.

Download Full-text